Literature DB >> 18094409

Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications.

Karène Mahtouk1, Dirk Hose, John De Vos, Jérôme Moreaux, Michel Jourdan, Jean François Rossi, Thierry Rème, Harmut Goldschmidt, Bernard Klein.   

Abstract

Multiple myeloma is a B-cell neoplasia characterized by the proliferation of a clone of malignant plasma cells in the bone marrow. We review here the input of gene expression profiling of myeloma cells and of their tumor microenvironment to develop new tumor classifiers, to better understand the biology of myeloma cells, to identify some mechanisms of drug sensitivity and resistance, to identify new myeloma growth factors, and to depict the complex interactions between tumor cells and their microenvironment. We discuss how these findings may improve the clinical outcome of this still incurable disease.

Entities:  

Mesh:

Year:  2007        PMID: 18094409      PMCID: PMC2910740          DOI: 10.1158/1078-0432.CCR-07-1758

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  62 in total

1.  Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease.

Authors:  Florence Magrangeas; Valéry Nasser; Hervé Avet-Loiseau; Béatrice Loriod; Olivier Decaux; Samuel Granjeaud; François Bertucci; Daniel Birnbaum; Catherine Nguyen; Jean-Luc Harousseau; Régis Bataille; Rémi Houlgatte; Stéphane Minvielle
Journal:  Blood       Date:  2003-03-06       Impact factor: 22.113

2.  Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays.

Authors:  Dharminder Chauhan; Guilan Li; Daniel Auclair; Teru Hideshima; Paul Richardson; Klaus Podar; Nicholas Mitsiades; Constantine Mitsiades; Cheng Li; Ryung Suk Kim; Nikhil Munshi; Lan Bo Chen; Wing Wong; Kenneth C Anderson
Journal:  Blood       Date:  2002-12-12       Impact factor: 22.113

Review 3.  The TNF family members BAFF and APRIL: the growing complexity.

Authors:  Fabienne Mackay; Christine Ambrose
Journal:  Cytokine Growth Factor Rev       Date:  2003 Jun-Aug       Impact factor: 7.638

4.  Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation.

Authors:  Katja Brocke-Heidrich; Antje K Kretzschmar; Gabriele Pfeifer; Christian Henze; Dennis Löffler; Dirk Koczan; Hans-Jürgen Thiesen; Renate Burger; Martin Gramatzki; Friedemann Horn
Journal:  Blood       Date:  2003-09-11       Impact factor: 22.113

5.  Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis.

Authors:  Faith E Davies; Ann M Dring; Cheng Li; Andrew C Rawstron; Masood A Shammas; Sheila M O'Connor; James A L Fenton; Teru Hideshima; Dharminder Chauhan; Isabella T Tai; Elizabeth Robinson; Daniel Auclair; Karen Rees; David Gonzalez; A John Ashcroft; Ranjit Dasgupta; Constantine Mitsiades; Nicholas Mitsiades; Lan B Chen; Wing H Wong; Nikhil C Munshi; Gareth J Morgan; Kenneth C Anderson
Journal:  Blood       Date:  2003-08-28       Impact factor: 22.113

6.  Molecular sequelae of proteasome inhibition in human multiple myeloma cells.

Authors:  Nicholas Mitsiades; Constantine S Mitsiades; Vassiliki Poulaki; Dharminder Chauhan; Galinos Fanourakis; Xuesong Gu; Charles Bailey; Marie Joseph; Towia A Libermann; Steven P Treon; Nikhil C Munshi; Paul G Richardson; Teru Hideshima; Kenneth C Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

7.  Single versus double autologous stem-cell transplantation for multiple myeloma.

Authors:  Michel Attal; Jean-Luc Harousseau; Thierry Facon; François Guilhot; Chantal Doyen; Jean-Gabriel Fuzibet; Mathieu Monconduit; Cyrille Hulin; Denis Caillot; Reda Bouabdallah; Laurent Voillat; Jean-Jacques Sotto; Bernard Grosbois; Regis Bataille
Journal:  N Engl J Med       Date:  2003-12-25       Impact factor: 91.245

8.  The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

Authors:  Erming Tian; Fenghuang Zhan; Ronald Walker; Erik Rasmussen; Yupo Ma; Bart Barlogie; John D Shaughnessy
Journal:  N Engl J Med       Date:  2003-12-25       Impact factor: 91.245

Review 9.  Survival and proliferation factors of normal and malignant plasma cells.

Authors:  Bernard Klein; Karin Tarte; Michel Jourdan; Karene Mathouk; Jerome Moreaux; Eric Jourdan; Eric Legouffe; John De Vos; Jean François Rossi
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.490

10.  Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells.

Authors:  Paula A Croonquist; Michael A Linden; Fangyi Zhao; Brian G Van Ness
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

View more
  8 in total

1.  B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.

Authors:  Yu-Tzu Tai; Kenneth C Anderson
Journal:  Expert Opin Biol Ther       Date:  2019-07-11       Impact factor: 4.388

2.  Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.

Authors:  Karène Mahtouk; Jérôme Moreaux; Dirk Hose; Thierry Rème; Tobias Meissner; Michel Jourdan; Jean François Rossi; Steven T Pals; Hartmut Goldschmidt; Bernard Klein
Journal:  BMC Cancer       Date:  2010-05-13       Impact factor: 4.430

3.  Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b.

Authors:  Katia Todoerti; Valentina Barbui; Olga Pedrini; Marta Lionetti; Gianluca Fossati; Paolo Mascagni; Alessandro Rambaldi; Antonino Neri; Martino Introna; Luigia Lombardi; Josée Golay
Journal:  Haematologica       Date:  2009-08-27       Impact factor: 9.941

4.  APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.

Authors:  Yu-Tzu Tai; Chirag Acharya; Gang An; Michele Moschetta; Mike Y Zhong; Xiaoyan Feng; Michele Cea; Antonia Cagnetta; Kenneth Wen; Hans van Eenennaam; Andrea van Elsas; Lugui Qiu; Paul Richardson; Nikhil Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2016-04-28       Impact factor: 22.113

5.  The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.

Authors:  Anne Catherine Sprynski; Dirk Hose; Laurent Caillot; Thierry Réme; John D Shaughnessy; Bart Barlogie; Anja Seckinger; Jérôme Moreaux; Michael Hundemer; Michel Jourdan; Tobias Meissner; Anna Jauch; Karène Mahtouk; Alboukadel Kassambara; Uta Bertsch; Jean François Rossi; Hartmut Goldschmidt; Bernard Klein
Journal:  Blood       Date:  2009-02-18       Impact factor: 22.113

6.  Niche-modulated and niche-modulating genes in bone marrow cells.

Authors:  Y Cohen; O Garach-Jehoshua; A Bar-Chaim; A Kornberg
Journal:  Blood Cancer J       Date:  2012-12-14       Impact factor: 11.037

7.  Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.

Authors:  Antonio Garcia-Gomez; Javier De Las Rivas; Enrique M Ocio; Elena Díaz-Rodríguez; Juan C Montero; Montserrat Martín; Juan F Blanco; Fermín M Sanchez-Guijo; Atanasio Pandiella; Jesús F San Miguel; Mercedes Garayoa
Journal:  Oncotarget       Date:  2014-09-30

8.  Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?

Authors:  Anouk Caraux; Laure Vincent; Salahedine Bouhya; Philippe Quittet; Jérôme Moreaux; Guilhem Requirand; Jean-Luc Veyrune; Gaëlle Olivier; Guillaume Cartron; Jean-François Rossi; Bernard Klein
Journal:  Oncotarget       Date:  2012-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.